Advertisement
Advertisement
June 2, 2021
Avicenna.AI’s Cina Chest Triage Solution Gains CE Mark and FDA Clearance
June 2, 2021—Avicenna.AI, a France-based company focusing on medical imaging artificial intelligence (AI) technology, announced that it has received CE Mark approval in Europe and FDA 510(k) clearance in the United States for the Cina Chest AI solution for emergency triage of vascular conditions.
According to the company, Cina Chest features automatic detection and triage capabilities for both pulmonary embolism (PE) and aortic dissection (AD) from CT imaging.
The technology provides automatic PE detection on CT chest angiography with accurate, rapid, real-time alerts on the disease. Additionally, Cina Chest identifies acute AD cases that require urgent intervention with accurate, real-time alerts on thoracoabdominal CTA.
Cina Chest is part of Avicenna’s Cina family of AI tools that support the treatment of emergencies, including the Cina Head solution that supports the detection and triage of stroke and neurovascular emergencies. Cina Head has received CE Mark approval and FDA clearance, as announced in July 2020.
Avicenna.AI’s medical imaging AI solutions leverage deep learning algorithms to identify acute abnormalities and support emergency room triage, stated the company.
Advertisement
Advertisement
